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Abstract
Background: A successful host immune response to infection is dependent upon both innate and adaptive immune
effector mechanisms. Cutaneous leishmaniasis results in an adaptive Th1 CD4+ T cell response that efficiently clears the
parasite, but may also result in scaring. However the role of innate mechanisms during parasite clearance remains less
well defined.
Methods: We examined a unique cohort of individuals, living in a Leishmania major endemic region, that were stratified
among 3 distinct clinical groups in a cross-sectional study. Specifically, patients were classified either as healed (n = 17),
asymptomatic (23), or naïve to infection (18) based upon the classical Leishmanin Skin Test (LST) and the presence or
absence of scars. Utilizing a multiplexed immunoassay approach we characterized the induced cytokine and chemokine
response to L. major.
Results: A subset of innate immune molecules was induced in all groups. By contrast, T cell-associated cytokines were
largely induced in exposed groups as compared to L. major-infection naïve individuals. Two exceptions were IL-17A and
IL-12p70, induced and not induced, respectively, in naïve individuals. In addition, GM-CSF was more strongly induced in
healed patients as compared to the other two groups. Surprisingly an IL-13 response was the best cytokine for classifying
previously infected donors.
Conclusions: Exploratory data analysis, utilizing principle component analysis (PCA), revealed distinct patient clusters of
the healed and naïve groups based on the most differentially induced proteins. Asymptomatic previously infected
individuals were more difficult to assign to a particular cluster based on these induced proteins. Analysis of these proteins
may enable the identification of biomarkers associated with disease, leading to a better understanding of the protective
mechanisms of immune response against leishmaniasis.
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Background
Leishmaniasis is a parasitic disease endemic in 98 coun-
tries with more than 350 million people at risk worldwide
[1], and approximately 1.3 million new cases and 20 000
to 30 000 deaths occur annually [2]. Zoonotic cutaneous
leishmaniasis (ZCL), caused by Leishmania major, is en-
demic in Tunisia, since epidemic emergence in 1982 in
Kairouan and expansion to the center and the south [3].
L. major is transmitted by the sand fly vector, Phleboto-
mus papatasi, and transmission is greatest from May to
September. Infected humans can develop disease (ZCL le-
sions) between October and May [4]. Infected sand fly
bites can lead to the development of cutaneous leishman-
iasis, possibly resulting in scaring and a parasite-specific
delayed-type hypersensitivity response as assessed by a
positive Leishmanin Skin Test (LST) reaction. However
this description is an oversimplification of the clinical sce-
nario observed in exposed individuals. Field studies sug-
gest that asymptomatic infection with L. major may occur
in endemic areas but the extent of this phenomenon has
not been fully evaluated [5].
Anti-Leishmania immunity is mediated by innate and
adaptive immunity, with the CD4+ T cell subset crucial for
resistance. Activated macrophages play a pivotal role in
Leishmania infection through effective clearance of all
forms of leishmaniasis [6]. Phagocytosis of parasites by
macrophages induces the release of multiple chemoattract-
ant factors, such as CXCL1, leading to recruitment of other
innate immune cells [7]. Dendritic cells (DCs) also play a
vital role in the production of IL-12 and type 1 IFNs, lead-
ing to activation of natural killer (NK) cells, IFN-γ produc-
tion, and subsequent Th1 responses [8]. The magnitude of
IL-12 production by infected DCs can critically affect the
outcome of L. major infection [9] and can act in combin-
ation with IL-1α/β to influence Th1 T cell development
and resistance to cutaneous infection [10]. The down-
stream result of IFN-γ and TNFα production is the gener-
ation of nitric oxide (NO) [11], a powerful cytostatic and
cytotoxic molecule that plays a major role in killing many
intracellular parasites, including Leishmania. However,
Leishmania parasites possess the ability to modify the im-
mune responses of their host to facilitate establishment of
progressive infection. For example, mouse studies have
shown that Leishmania induced IL-13 promotes disease
[12–15], and numerous studies have identified a central
role for IL-10 in susceptibility, immunopathology, and
parasite persistence [16–18].
Stimulated PBMCs from patients are often used to as-
sess immune function and evidence of previous or current
infections. In this study we aimed to characterize the in-
duced cytokine profile of individuals living in endemic
areas of L. major transmission with different clinical
features and a classically defined exposure history. In
depth analysis of these immune profiles may allow the
identification of biomarkers associated with disease
outcome giving us a better understanding of the mech-
anisms behind protective human immune responses
against leishmaniasis.
Methods
Study population and design
Our cross-sectional study population consisted of 58 indi-
viduals aged 7 to 18 years, living in an endemic area for
ZCL due to L. major in the governorate of Sidi Bouzid
and Kairouan in central Tunisia (Table 1). A physical and
detailed skin examination was performed on each partici-
pant. The history of ZCL was assessed by the presence of
typical scars, and blood samples were taken and the LST
was administered. Individuals were subdivided according
to the LST response (LST+ or LST-) and the presence of
scars (SCAR+ or SCAR-). Within our study cohort there
were 17 healed individuals (LST + SCAR+), 23 asymptom-
atic individuals (LST + SCAR-), and 18 naïve individuals
(LST-SCAR-) (Table 1). All donors were recruited and
samples taken during the months of April and May prior
to the season of parasite transmission.
Ethical statement
The study protocol was approved by the Institutional
Review Board of the Pasteur Institute of Tunis. All sub-
jects provided written informed consent for participation
in the study and sample collection and analyses. For mi-
nors under the age of 18, written informed consent was
obtained from a parent or guardian. The study was ex-
ternally monitored for protocol agreement, data integ-
rity, and protection of human subjects. For inclusion in
our study we identified and selected individuals living in
a Leishmania endemic area, aged 7 to 18 years old, who
underwent a clinical examination to assess the presence
or absence of ZCL history, and for whom an LST was
Table 1 Demographic and clinical features of the study population
Cutaneous Leishmania (LST + SCAR+) Asymptomatic (LST + SCAR-) Naïve (LST-SCAR-)
- Donor numbers 17 23 18
- Age, mean ± SD (range), years 12.9 ± 3.5 (7–18) 13.2 ± 3.6 (7–18) 13.3 ± 4.4 (7–18)
- Zoonotic Cutaneous Leishmaniasis scars yes no no
- Leishmanin Skin Test (LST) positive yes yes no
- LST induration, mean ± SD (range), mm 12.3 ± 4.5 (5,5-21) 12.1 ± 5.6 (5–24,5) 0,1 ± 0,7 (0–3)
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performed. Exclusion criteria included immunodepres-
sion, pregnancy, and individuals who did not enable the
LST interpretation in a follow up visit.
Leishmanin skin test
LST was performed by intradermal injection of 100 μl of
L. major suspension containing 5 x 106 L. major promas-
tigotes in 1 ml 0.5 % phenol saline. After 72 h, the indur-
ation was measured along 2 diameters by the ballpoint
pen technique [19]. Induration with a diameter of 5 mm
or more indicated a positive test [20–23].
Parasite culture
L. major parasites (MHOM/TN/94/GLC94, zymodeme
MON25) were cultured in Novy–Nicolle–McNeal medium
at 26 °C and progressively adapted to RPMI 1640 medium
(Sigma, St Louis, Mo) containing 2 mM L-glutamine
(Sigma) 100 U/ml penicillin (Sigma), 100 mg/ml strepto-
mycin (Sigma) and 10 % heat-inactivated fetal calf serum
(FCS) (Invitrogen, CergyPontoise, France). Metacyclic pro-
mastigotes were isolated from day 6 stationary cul-
tures by a discontinuous Ficoll gradient as previously
described [24, 25].
Isolation of human peripheral blood mononuclear cells
(PBMCs) and cell stimulation
PBMCs were separated from heparinized blood samples
using Ficoll/Hypaque (GE Healthcare, Uppsala) density gra-
dient centrifugation. 1 x 106 cells/ml were stimulated with
live L. major parasite (3 parasites/cell), and with culture
media as a negative control. Culture supernatants were col-
lected after 48 hours and conserved at −80 °C until protein
immunoassay testing.
Multi-analyte protein immunoassays
Seventeen cytokines and chemokines were analysed by
Luminex using an extended human Th1/Th2 12-plex
(IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13,
GM-CSF, TNFα, IL-18) and a custom made 6 plex (MIP-
1α, IL-8, IL-17A, IFN-γ, MCP-1, M-CSF), according to the
manufacturer’s instructions (Affymetrix, eBioscience).
As IFN-γ was used as a positive control for infection, it was
included in both Luminex assays and allowed for norma-
lization between the two separately run assays. Results
were expressed in pg/ml, and for data mining purposes,
any samples with no measurable value were given a value
that was half of the lowest detectable dose of the assays.
IL-4 was not detected in any conditions so results are not
presented, and MCP-1 was excluded due to technical rea-
sons. All data is available in Additional file 1: Table S1.
Statistical analysis
Wilcoxon matched-pairs tests were applied within clin-
ical groups to test for a significant (p < 0.05) effect of
parasite stimulation (GraphPad Prism). To test for sig-
nificant differences (p < 0.05) between groups a Kruskal
Wallis test with Dunn’s multiple test comparison was
applied (GraphPad Prism). The sensitivity, specificity,
positive and negative predictive values of the induced
cytokine responses for IFN-γ, IL-2, IL-18, IL-12p70, and
IL-13 for classifying LST+ (n = 40) individuals as com-
pared to LST- (n = 18) with a 95 % confidence interval
were calculated using GraphPad Prism. Principal compo-
nent analysis (PCA) was applied for mutli-variate ana-
lyses on log transformed L. major-induced responses
with p and q values reported following ANOVA testing
(Qlucore Omics Explorer 3.1).
Results
Characterization of the adaptive immune response in LST+
individuals
The LST is a widely utilized method for evaluating an indi-
vidual’s immune response to Leishmania infection. It is
dependent on a delayed type hypersensitivity reaction, me-
diated by Th1 IFN-γ+ T cells, and indicates a previous
infection and subsequent adaptive immune response. We
confirmed a significant Leishmania specific IFN-γ response
in the LST + SCAR+ and LST + SCAR- individuals, but not
the LST-SCAR- naïve group following PBMC parasite
stimulation (Fig. 1a). Utilizing Luminex multi-analyte assays
we tested additional cytokines for potential differences
among the cohort following PBMC parasite stimulation.
Cytokines which showed a significant induction (Wilcoxon
paired T test, p < 0.05) in the LST + SCAR+ and LST +
SCAR- groups included IL-2, IL-18, IL-12p70, and IL-13
(Fig. 1b-e). Some LST-SCAR- donors secreted low amounts
of IFN-γ, IL-2, IL-18, and IL-13 (Fig. 1a, b) but when ana-
lyzed as a group this response was not statistically signifi-
cant. To test for potential utility in classifying patients we
tested each cytokine for its sensitivity, specificity, positive
and negative predictive values to characterise LST+ versus
LST- patients (Table 2). Surprisingly IL-13 gave the best
overall results with 100 % specificity and 86 % sensitiv-
ity, slightly superior than IFN-γ (92 % specificity and
86 % sensitivity). For IL-12p70 we had 92 % sensitivity
though this result should be interpreted with caution as
many of the values were close to the limit of detection
of the assay. IFN-γ, IL-2 and IL-13 are all produced by
T cells, but as IL-18, and IL-12p70 are produced by
monocytes or dendritic cells we tested for other cyto-
kines classically produced by these cell types across the
3 groups.
Shared induced innate immune responses across all 3
clinical groups
In addition to the infection specific responses we observed
a number of cytokines that were commonly induced in all
groups following PBMC stimulation with L. major parasite,
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Fig. 1 Characterization of the adaptive immune response in LST+ individuals. Secreted cytokines, (a) IFN-γ, (b) IL-2, (c) IL-18, (d) IL-12p70, and (e)
IL-13 measured by Luminex assays following Leishmania parasite stimulation of PBMCs from donors subdivided into 3 clinical groups, according
to the Leishmanin skin test response (LST+/−) and presence or absence of specific scars (SCAR+/−). (***) denotes p < 0.001 as determined by
Wilcoxon paired T test, samples with no measurable value were given a value that was half of the lowest detectable dose of the assays)
Table 2 The sensitivity, specificity, positive predictive values, and negative predictive values of the induced cytokine response for
IFNγ, IL-2, IL-18, IL-12p70, and IL-13 for identifying LST+ (n = 40) individuals as compared to LST- (n = 16) with a 95 % confidence
interval
Sensitivity Specificity Positive predictive value Negative predictive value
IFN-γ 0.86 0.92 0.97 0.66
IL-2 0.76 0.85 0.97 0.33
IL-18 0.87 0.76 0.9 0.72
IL-12p70 0.92 0.48 0.57 0.88
IL-13 0.86 1.00 1.00 0.66
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as determined by Wilcoxon paired T tests to non-
stimulated controls (p <0.05) (Fig. 2). MIP-1α and IL-1β are
two crucial innate immune mediators that were signifi-
cantly induced in response to L. major parasites with little
variation among the different clinical groups (Fig. 2a, b).
However there was large variation (up to 2 log) between all
individuals for the IL-1β, but not MIP-1α response. PBMCs
from the three groups also commonly produced M-CSF
and IL-10, though there were non-responders in all groups
for M-CSF, and within the LST-SCAR- group for IL-10
(Fig. 2c, d). Of note the three IL-10 non-responders were
high responders for M-CSF. Finally IL-17A, TNF-α, IL-5,
and GMCSF were also induced in all groups following
parasite stimulation (Fig. 2e-h). However IL-17A, TNF-
α, and IL-5 were produced at significantly (p <0.05) higher
levels in the previously infected donors compared to naïve
Fig. 2 Shared induced innate immune responses across all 3 clinical groups. Secreted cytokines significantly induced (Wilcoxon paired T test, p < 0.05)
(a) MIP-1α, (b) IL-1β, (c) M-CSF, (d) IL-10, (e) IL-17A, (f) TNFα, (g) IL-5, and (h) GMCSF measured by Luminex assays following Leishmania parasite
stimulation of PBMCs from donors subdivided into 3 clinical groups, according to the Leishmanin skin test response (LST+/−) and presence or absence
of specific scars (SCAR+/−). (*** denotes p < 0.001, ** p < 0.01, * p < 0.05 as determined by Kruskal Wallis test with Dunn’s multiple testing between the
3 groups, samples with no measurable value were given a value that was half of the lowest detectable dose of the assays)
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individuals, (Fig. 2e-g). Finally, GMCSF was significantly
(p <0.05) higher in LST + SCAR+ compared to both LST
+ SCAR- and LST-SCAR- individuals.
Lack of induced response to Leishmania parasite for key
inflammatory molecules
Two key inflammatory molecules, IL-6 and IL-8, did not
show a significant difference following PBMC stimulation
with the parasite in all 3 groups. IL-6 showed a clear bi-
modal distribution across all 3 groups, independent of para-
site stimulation (Fig. 3a). However some individuals
showed high levels of IL-6 either in the presence or absence
of ex vivo parasite stimulation, suggesting that this cytokine
may reflect another infectious or inflammatory process. IL-
8, another key inflammatory modulator, also showed no
significant induction following parasite stimulation across
all 3 groups (Fig. 3b). This may reflect the PBMC stimula-
tion where only monocytes but not neutrophils, of the main
IL-8 producing cells, are present in this cell preparation.
There was a trend towards higher overall IL-8 in the naïve
donors, although this may be due to the higher variability
in this group, as detected by a Bartlett’s test.
Multivariate protein analysis reveals distinct patterns for
LST + SCAR+ and LST-SCAR- groups
To examine the complete response in a multivariate ap-
proach, we applied principle component analysis to all
donors based on the 10 most differential proteins, as iden-
tified by a multi-group ANOVA (p <0.002, q <0.004). This
revealed a clustering of the LST + SCAR+ group and the
LST-SCAR- group mainly along the first principle compo-
nent (Fig. 4a). The LST + SCAR- group clustered less
clearly with some individuals clustering closer to the
scarred group, and some to the naïve individuals. This in-
dicates the heterogeneity within this group in terms of
their induced immune response to the parasite. The first
principle component (PC1), which comprised 61 % of the
variance within the data set, was largely driven by IFN-γ
and other T cell cytokines such as IL-2, IL-13, and IL-18.
This is illustrated by a heat map overlay of IFN-γ protein
levels on the PCA donor plot (Fig. 4b), and the list of pro-
teins in order of significant differences as determined by
ANOVA (Fig. 4e). PC2 which comprised 13 % of the vari-
ance, was mostly driven by MCP-1, IL-6, and GM-CSF
suggesting a monocyte response. However this signature
did not overlap with any of the clinical characteristics ex-
amined. PC3, which comprised 6 % of the total variance,
was largely due to the IL-17A response which was higher
in a subset of donors that were LST+. To discriminate the
LST-SCAR- donors more clearly, we performed PCA in
separate combinations with the other 2 groups. This con-
firmed a clear separation of uninfected donors from the
LST + SCAR+ group, with a less clear distinction from the
LST + SCAR- group (Fig. 4c-d).
Discussion
The definition of immuno-pathological and immuno-
protective mechanisms during human infection is diffi-
cult to achieve due to heterogeneity of both human
genetic backgrounds and microbial populations. As such,
human studies of the cellular immune responses during
leishmaniasis are often descriptive or indirectly studied. In
an attempt to counter some of these limitations, we exam-
ined a unique cohort of individuals living in a region
endemic for ZCL, within which donors had 3 distinct clin-
ical manifestations: exposed healed, exposed asymptomatic,
and naïve, for whom we performed a multi-protein analysis
following ex vivo parasite PBMC stimulation.
We confirmed the presence of a strong Th1 T cell re-
sponse in previously infected individuals with a signifi-
cant production of IFN-γ and IL-2. Experimental models
of infection with Leishmania have been used to establish
the importance of the Th1 immune response, whereas
the Th2 response has been found to be associated with
disease susceptibility [26]. However studies of human
immunological responses have shown that the Th1/Th2
Fig. 3 Lack of induced response to Leishmania parasite for key inflammatory molecules. Cytokines (a) IL-6, (b) IL-8 with no differences as measured by
Luminex assays following parasite stimulation of PBMCs from donors subdivided into 3 clinical groups, according to the Leishmanin skin test response
(LST+/−) and presence or absence of specific scars (SCAR+/−)
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dichotomy shown in experimental animal models is not
as evident in humans [26]. Higher IFN-γ production in
individuals recovered from CL, and LST+ individuals
without a history of CL, as compared to healthy controls
has been previously reported by others [5, 27, 28]. In the
LST+ donors, as well as detecting a strong IFN-γ re-
sponse, we also observed a low but significant produc-
tion of IL-13 [29]. This cytokine has been described as a
susceptibility factor for L. major infection in mice [14],
but data about IL-13 during human Leishmania infec-
tion are scarce. It was shown that IL-13 was the central
mediator for maintaining Th2 development in human
CL due to L. guyanensis by rendering specific cells
unresponsive to IL-12 [30]. More recently, it was reported
that IL-13 levels were similar in individuals with a history
of self-healing CL due to L. major and healthy controls in
response to soluble Leishmania antigen stimulation [31].
These differing results may be explained by substrain or
species differences of Leishmania parasites and/or the dif-
ferent stimuli used (eg soluble antigen vs live parasites).
Given the detection of IL-13, the lack of IL-4 in all cul-
tures was surprising, as these cytokines share a common
signalling pathway through the IL-4Rα chain and have
previously been implicated in non-healing response to L.
major infection in mice [32]. While this may reflect the
kinetics of the stimulation system, or the sensitivity of the
a b
c
e
d
Fig. 4 Multivariate protein analysis. Principal component analysis (PCA) of LST + SCAR+ (blue), LST + SCAR- (yellow), and LST-SCAR- (pink) donors
(a) based on the 10 most significantly differential proteins as identified by multi ANOVA (q < 0.01), (b) heat map overlay of IFN-γ expression.
PCA of (c) LST + SCAR+ (blue) and LST-SCAR- (pink) donors, (d) LST + SCAR- (yellow) and LST-SCAR- (pink) donors. Numbers represent percentage of
variance captured by each principal component. (e) List of most differential proteins with p and q values as determined by multi ANOVA testing
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assays, it also highlights the complexity of cytokines and
their often pleiotropic responses potentially determined
by the local cellular microenvironment and overall im-
mune status of the host.
Previously infected donors also showed a robust pro-
duction of IL-18 and significant but low levels of IL-
12p70, most likely produced by monocytes following
parasite encounter. In the naïve group, we observed that
a minority of donors secreted reduced levels of IFN-γ,
IL-2, and IL-13, suggesting some low level immunity to
the parasite. Interestingly the non-infected group secreted
high amounts of IL-1β, without induction of IL-18. This
was striking as these two cytokines are inflammasome-
dependent. One possible explanation is that the initial
production of IL-18 is dependent on the presence of adap-
tive cytokines only secreted in LST+ donors. A recent
study showed that both cytokines were produced during
L. major infection in mice [33], however the consequence
of IL-18 induction for infection outcome is less clear.
Some studies have shown a positive role for IL-18 through
the amplification of Th1 responses, but others have shown
a potential for biasing Th2 responses and infection sus-
ceptibility [33–35]. In contrast IL-1β has been shown to
play a protective role through the downstream induction
of nitric oxide by macrophages [36].
Notably, we observed significant IL-17A and TNF-α
secretion by all donors, including naïve individuals who
showed no evidence of IFN-γ production. Both of these
cytokines have previously been associated with disease-
induced immunopathology, with CD4+ T cells believed
to be the main source during active disease [37, 38]. IL-
17 is associated with inflammation and recruitment of
neutrophils to the infection site during L. major infec-
tion in humans [39, 40] and as such may play a role in
tissue damage at the site of infection.
The identification of IL-17-producing cells in PBMCs of
naïve donors requires further study, as the major cell types
previously identified to produce this cytokine are CD4+ T
cells, and in some cases neutrophils. The role of IL-17
during Leishmania infection is controversial. IL-17 pro-
moted progression of CL in L. major-infected mice via
regulation of neutrophil recruitment [41, 42], whereas in
L. infantum-infected mice it was shown to promote the
control of parasite replication by acting synergistically
with IFN-γ to potentiate NO production [43]. In humans,
IL-17 is associated with inflammation and recruitment of
neutrophils at the infection site during L. braziliensis in-
fection [29, 30] whereas in VL it is associated with protec-
tion [44]. To our knowledge our study is the first to report
the presence of an IL-17A response in individuals immune
to L. major.
GM-CSF was produced at significantly higher levels in
both infected groups compared to naïve donors. In
addition it showed a strong positive correlation (>75 %,
p < 0.0001) with both TNF-α and IL-5, which shared the
same pattern of higher production in infected asymp-
tomatic patients. This interesting finding of significantly
higher levels of GM-CSF found in individuals with previ-
ous ZCL compared to both asymptomatic and naïve in-
dividuals, could suggest that individuals predisposed to
higher production of GM-CSF may be at risk for devel-
oping clinical disease when infected with Leishmania.
High levels of GM-CSF favour macrophage recruitment
and differentiation, the main target population in which
Leishmania has evolved strategies for efficient uptake
and survival. These results are in agreement with a pre-
vious study demonstrating successful treatment of re-
fractory CL with GM-CSF and antimonials [45].
Whether the differential expression of these cytokines
influences the clinical manifestation of disease, or is a dir-
ect reflection of disease requires further study. However
these results show promise for new diagnostic approaches
based on the measurement of induced immune responses,
as opposed to the crude LST test, which requires an inva-
sive skin injection of parasite in phenol solution. The use
of secreted IFN-γ as a biomarker to replace the LST test
has already been proposed [46]. However the inclusion of
additional protein biomarkers may improve diagnostic ac-
curacy. For example, in our cohort IL-13 showed greater
specificity than IFN-γ for the identification of LST+ pa-
tients. To fully capitalize on the application of multi-
analyte protein testing in diagnostic settings new analytical
approaches are required. As some of these methods,
which include principal component analysis, have recently
been used to identify potential biomarkers in HIV [47]
and viral hepatitis [48], we applied this approach to our
patient data set. While it did not reveal new findings per
se, this approach illustrated the heterogeneous nature of
the asymptomatically infected patients. In addition it con-
firmed the presence of an adaptive immune response that
segregated LST+ from LST- patients, and an innate im-
mune signature that did not help patient segregation.
While the use of more classical statistical approaches iden-
tified potential biomarker combinations with improved
diagnostic accuracy, larger validation studies, as well as
more standardized methods of ex vivo stimulation [49], will
be required to validate these findings. In addition, these
new approaches may aid in the elucidation of the pre-
cise mechanisms and role of cytokines in leishmaniasis
pathology.
Conclusion
Our study provides new insights into leishmaniasis by
showing distinct clusters of healed and naïve patient
groups based on the most differentially induced proteins
following ex vivo parasite stimulation. Asymptomatic in-
dividuals were more difficult to assign to a particular
cluster based on these induced proteins. These proteins
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deserve further consideration to identify biomarkers as-
sociated with disease outcome.
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